Study EV-103 cohort H: Neoadjuvant treatment with enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) with muscle invasive bladder cancer (MIBC)—3-year efficacy results.
Mar N, Petrylak D, Hoimes C, Rosenberg J, Flaig T, Gourdin T, Barata P, Henry E, Bilen M, George S, Rao S, Assikis V, Burgess E, Lewis B, Srinivas S, Gorla S, Meng C, Zhu Y, O'Donnell P. Study EV-103 cohort H: Neoadjuvant treatment with enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) with muscle invasive bladder cancer (MIBC)—3-year efficacy results. Journal Of Clinical Oncology 2025, 43: 4583-4583. DOI: 10.1200/jco.2025.43.16_suppl.4583.Peer-Reviewed Original ResearchMedian event-free survivalPathological complete responseEvent-free survivalInvestigator assessmentEnfortumab vedotinEfficacy resultsOS ratesNeoadjuvant treatmentSafety profileFollow-upPathologic complete response ratePelvic lymph node dissectionEvent-free survival rateAntitumor activityLong-term follow-upCentral pathology reviewEstimated OS ratesNeoadjuvant treatment optionsLymph node dissectionMedian Follow-UpPhase 3 trialCT2-T4aN0M0Median OSConsistent with prior reportsComplete response
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply